Antisense oligonucleotide therapies for monogenic disorders

Area of Science:

• Biotechnology
• Genetics
• Pharmacology

Background:

• Antisense oligonucleotides (ASOs) represent a significant advancement in treating monogenic disorders by enabling precise RNA targeting.
• Despite initial challenges in delivery and potential toxicity, ASO therapies have progressed significantly, with approved drugs and numerous clinical trials underway.
• The therapeutic scope of ASOs is expanding across various fields, including neurogenetic, metabolic, and oncologic diseases, with novel n-of-1 applications for ultra-rare conditions.

Purpose of the Study:

• To elucidate the diverse mechanisms of action employed by antisense oligonucleotides (ASOs) based on their chemical properties.
• To outline the criteria for selecting patients suitable for ASO therapy.
• To emphasize the integral role of human genetics in guiding patient selection and treatment decisions for ASO therapies.

Main Methods:

• Review of existing literature on antisense oligonucleotide (ASO) chemistry and mechanisms.
• Analysis of clinical trial data and approved ASO therapies.
• Exploration of genetic principles for patient stratification in ASO treatment.

Main Results:

• ASOs function through various RNA-targeting mechanisms dictated by their specific chemistry.
• Successful ASO therapies have been developed for a range of genetic disorders.
• Human genetics plays a pivotal role in identifying patient populations amenable to ASO treatment.

Conclusions:

• Antisense oligonucleotide (ASO) technology provides a versatile platform for treating genetic diseases by modulating gene expression.
• Careful consideration of ASO chemistry and patient genetics is essential for optimizing therapeutic outcomes.
• The integration of human genetics is key to advancing personalized ASO-based therapies.